Clinical trials: Metastatic Colorectal Neoplasms
Colorectal Carcinoma, Metastatic Colon Adenocarcinoma
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
This phase II trial studies how well savolitinib works in treating patients with MET amplified colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable).
- Conditions
- Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8
- Trial name
- NCT03592641
- Testing
- Savolitinib
- Where
- 33 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States
This is an observational study in which data already collected from patients with metastatic colorectal cancer will be studied. Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bowel) or the rectum (lowest part…
- Trial name
- COLONGER (NCT06029010)
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- United States
- Volunteers
- 2,326 people
- Sponsor
- Bayer
Breast Cancer, Colorectal Cancer
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- NCT00709462
- Testing
- CDX1307
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Celldex Therapeutics
Non Metastatic Colorectal Cancer
Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patients With Nonmetastatic Colorectal Cancer
Evaluate the patient care recommandation induced by the IMMUNOSCORE® result
- Trial name
- NCT04938986
- Testing
- IMMUNOSCORE®
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Hospital St. Joseph, Marseille, France
Colorectal Cancer
ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of colorectal cancer.
- Trial name
- NCT00030524
- Testing
- gefitinib
- Where
- 2 sites in United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
This phase Ib/II trial investigates the side effects and best dose of LY3214996 when given together with cetuximab alone or in combination with abemaciclib and to see how well they work in treating patients with colorectal cancer…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colorectal Carcinoma
- Trial name
- NCT04616183
- Testing
- Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Neoplasms
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
This two-stage study is designed to compare the safety and activity between RRx-001 against regorafenib followed by irinotecan-based therapies in a parallel comparative study.
- Trial name
- ROCKET (NCT02096354)
- Testing
- RRx-001, Regorafenib, Irinotecan
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- EpicentRx, Inc.
Rectal Cancer, Colon Cancer
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with either FOLFIRI or FOLFOX4 chemotherapy regimens. This is a Phase 1b clinical study.
- Trial name
- NCT00101894
- Testing
- FOLFOX-4, AMG 706, Panitumumab (Part 1a only)
- Volunteers
- 119 people
- Sponsor
- Amgen
Metastatic Colorectal Cancer, mCRC
LifePearl-Iri Pharmacokinetic Study
The primary purpose of the study is to evaluate the pharmacokinetic profile, safety, and efficacy of LifePearl microspheres loaded with irinotecan in the treatment of liver predominant mCRC by chemoembolization.
- Trial name
- NCT02547480
- Testing
- TACE with irinotecan loaded LifePearl
- Where
- 3 sites in Belgium, Germany
- Volunteers
- 15 people
- Sponsor
- Terumo Europe N.V.
Colorectal Cancer
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
This observational study will evaluate the use of Avastin (bevacizumab) and conventional chemotherapy in patients >/= 70 years of age with previously untreated metastatic colorectal cancer.
- Trial name
- NCT01676922
- Where
- 33 sites in Belgium
- Volunteers
- 256 people
- Sponsor
- Hoffmann-La Roche
Colon Cancer Patients Receiving Chemotherapy in the Adjuvant or Metastatic Setting, Aged 70 or Older
MOST: Mediterranean Oncology Senior Tests
MOST is a longitudinal study whose aim is to test the hypothesis that frailty markers are better at detecting vulnerable patients and that they are a better "Adverse Events" predictive tool than the CGA (Comprehensive Geriatric…
- Trial name
- MOST (NCT02148731)
- Testing
- Frailty markers
- Where
- 8 sites in France
- Volunteers
- 180 people
- Sponsor
- Association Sud pour la Recherche en Oncogériatrie
Colorectal Cancer, Pancreatic Cancer
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
Phase 1b study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with Balstilimab and Botensilimab for unresectable or metastatic mismatch repair-proficient…
- Trial name
- NCT06411691
- Testing
- KRAS Vaccine with Poly-ICLC adjuvant, Balstilimab, Botensilimab
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Colorectal Cancer
A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece
Collection of real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population.
- Trial name
- RETRO-TAS (NCT04965870)
- Testing
- Trifluridine/Tipiracil
- Where
- 8 sites in Greece
- Volunteers
- 200 people
- Sponsor
- Hellenic Study Group of Psychoneuroimmunology in Cancer
Metastatic Colorectal Cancer, Recurrent Colorectal Cancer
Phase I/II Trial of Antagonism of HER in GI Cancer
Recruitment to phase I of the PANTHER trial is complete. Phase II, is to evaluate the best overall response rate for AZD8931 + FOLFIRI treatment.
- Trial name
- PANTHER (NCT01862003)
- Testing
- AZD8931, Irinotecan, Folinic Acid
- Where
- 4 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- University College, London
Colorectal Cancer Metastatic
Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
Efficacy and safety of irinotecan liposomes combined with cetuximab + vermofenib in first-line failure of advanced RAS wild /BRAF mutated colorectal cancer, Exploratory analysis of biomarkers (including but not limited to ctDNA…
- Trial name
- VICPROIRI (NCT06763029)
- Testing
- Irinotecan liposomes combined with cetuximab + vermofenib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Fudan University
Rectal Neoplasms
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)
The purpose of this adaptive trial is to compare the progression-free survival of participants with metastatic rectal carcinoma when treated with intravenous (IV) dalotuzumab (MK-0646) + irinotecan therapy relative to…
- Trial name
- NCT01609231
- Testing
- Dalotuzumab, Irinotecan, Cetuximab
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer, Metastatic Colon Cancer
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
This research study is a randomized controlled trial that will observe changes in microbiome activity, changes in chemotherapy toxicity, and any changes in treatment outcomes between two groups of participants undergoing…
- Conditions
- Colorectal Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT06202183
- Testing
- Exercise Program
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Dana-Farber Cancer Institute
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin calcium, work in different ways to stop the growth…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00942266
- Testing
- fluorouracil, leucovorin calcium, vorinostat
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Roswell Park Cancer Institute
Liver Metastasis Colon Cancer
Study of Intra-Arterial Oxaliplatin Plus Capecitabine to Treat Liver Metastases From Colorectal Cancer
The treatment proposed in this trial is to administer intra-arterial chemotherapy to liver metastases from colorectal cancer when the blood flow to and from the liver has been isolated via balloon catheters through a vascular…
- Trial name
- SYS-CAPLIOX (NCT04701281)
- Testing
- Intra-arterial LIOX + Capecitabine
- Where
- 5 sites in Australia
- Volunteers
- 5 people
- Sponsor
- AllVascular
Metastatic Colo-rectal Cancer
FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer
The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy compared to FOLFIRI in a phase III trial. Panitumumab with oxaliplatin- or irinotecan-based doublets is feasible and associated with improved activity in KRAS…
- Trial name
- TRIP (NCT01358812)
- Testing
- FOLFOXIRI + Panitumumab
- Where
- 10 sites in Italy
- Volunteers
- 37 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.